Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MR, Bermúdez-Rodríguez MA, López-Corral L, Triguero A, Onstad L, Horwitz ME, Sarantopoulos S, Lee SJ, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Among authors: caballero velazquez t. Clin Cancer Res. 2023 Oct 13;29(20):4057-4067. doi: 10.1158/1078-0432.CCR-23-0666. Clin Cancer Res. 2023. PMID: 37698881
Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial.
Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético). Caballero-Velázquez T, et al. Clin Cancer Res. 2016 Dec 1;22(23):5673-5681. doi: 10.1158/1078-0432.CCR-16-0238. Epub 2016 Jun 29. Clin Cancer Res. 2016. PMID: 27358490 Clinical Trial.
Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms.
Carrillo-Cruz E, García-Lozano JR, Márquez-Malaver FJ, Sánchez-Guijo FM, Montero Cuadrado I, Ferra I Coll C, Valcárcel D, López-Godino O, Cuesta M, Parody R, López-Corral L, Alcoceba M, Caballero-Velázquez T, Rodríguez-Gil A, Bejarano-García JA, Ramos TL, Pérez-Simón JA. Carrillo-Cruz E, et al. Clin Cancer Res. 2019 Aug 1;25(15):4616-4623. doi: 10.1158/1078-0432.CCR-18-3875. Epub 2019 May 1. Clin Cancer Res. 2019. PMID: 31043390 Free article. Clinical Trial.
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Caballero-Velázquez T, et al. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772672 Free article. Clinical Trial.
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Free article. Clinical Trial.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA. López-Corral L, et al. Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3. Biol Blood Marrow Transplant. 2019. PMID: 31054983 Free article. Clinical Trial.
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies.
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-García R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á, Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C, Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón JA, Caballero-Velázquez T. García-Calderón CB, et al. Among authors: caballero velazquez t. Front Immunol. 2023 Apr 14;14:1152498. doi: 10.3389/fimmu.2023.1152498. eCollection 2023. Front Immunol. 2023. PMID: 37122702 Free PMC article.
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment.
Reinoso-Segura M, Caballero-Velázquez T, Herrera P, Patriarca F, Fanin R, Bruno B, Einsele H, Nahi H, Granell M, López-Corral L, Reguera JL, García-Cadenas I, Gahrton G, Pérez-Simón JA; European Myeloma Network, the European Society for Blood and Marrow Transplantation, and the Spanish Group of Transplantation. Reinoso-Segura M, et al. Transplant Cell Ther. 2022 May;28(5):258.e1-258.e8. doi: 10.1016/j.jtct.2022.01.026. Epub 2022 Feb 4. Transplant Cell Ther. 2022. PMID: 35131486 Free article. Clinical Trial.
Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.
Barbado MV, Medrano M, Caballero-Velázquez T, Álvarez-Laderas I, Sánchez-Abarca LI, García-Guerrero E, Martín-Sánchez J, Rosado IV, Piruat JI, Gonzalez-Naranjo P, Campillo NE, Páez JA, Pérez-Simón JA. Barbado MV, et al. Int J Cancer. 2017 Feb 1;140(3):674-685. doi: 10.1002/ijc.30483. Epub 2016 Nov 10. Int J Cancer. 2017. PMID: 27778331 Free article.
62 results